hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06352723, orgStudyIdInfo id: 2024P000856, briefTitle: Cenobamate in the Intensive Care Unit, acronym: CENOBITE, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2024-12, completionDateStruct date: 2025-06, studyFirstPostDateStruct date: 2024-04-08, lastUpdatePostDateStruct date: 2024-04-08, sponsorCollaboratorsModule leadSponsor name: Brigham and Women's Hospital, class: OTHER, descriptionModule briefSummary: The CENOBITE study will be conducted as a multi-center trial involving X leading centers from the Critical Care EEG Monitoring Consortium (CCEMRC). A total of 10 patients will be recruited over a period of one year, with each patient undergoing monitored treatment regimen. Each site will obtain its own approval from their institutional review board. Data will be shared through the MGB REDCap; raw EEG files will be shared through the MGB Dropbox and analyzed at the BWH.Monitoring for the development of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome, a potential adverse reaction, will be a key aspect of the study. Regular assessments, including RegiSCAR scoring (a validated scoring system for DREeSS5), daily serum cenobamate level measurements, and comprehensive lab tests, will be conducted to ensure patient safety and the effective management of any adverse reactions such as DRESS syndrome., conditionsModule conditions: Epilepsy, conditions: Neurologic Disorder, designModule studyType: INTERVENTIONAL, phases: EARLY_PHASE1, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: Single arm pilot study, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 10, type: ESTIMATED, armsInterventionsModule interventions name: Cenobamate, outcomesModule primaryOutcomes measure: Target level, primaryOutcomes measure: Maintenance level, secondaryOutcomes measure: Seizure cessation, secondaryOutcomes measure: Seizure burden change, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Brigham and Women's Hospital, city: Boston, state: Massachusetts, zip: 02115, country: United States, geoPoint lat: 42.35843, lon: -71.05977, hasResults: False
protocolSection identificationModule nctId: NCT06352684, orgStudyIdInfo id: DP0001-SEV-CAB-II, secondaryIdInfos id: RS-2023-00227526, type: OTHER_GRANT, domain: Korea Ministry of Science and ICT, briefTitle: Multi-Reader Multi-Case, Retrospective Study to Evaluate Effectiveness of CadAI-B for Breast, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2023-11-24, primaryCompletionDateStruct date: 2025-01-14, completionDateStruct date: 2025-01-14, studyFirstPostDateStruct date: 2024-04-08, lastUpdatePostDateStruct date: 2024-04-08, sponsorCollaboratorsModule leadSponsor name: BeamWorks Inc., class: INDUSTRY, collaborators name: Severance Hospital, descriptionModule briefSummary: The purpose of this study is to evaluate the effectiveness of lesion detection and diagnosis-aiding software (CadAI-B for Breast) during ultrasound (US) examination, conditionsModule conditions: Breast Cancer, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: RETROSPECTIVE, enrollmentInfo count: 1000, type: ACTUAL, armsInterventionsModule interventions name: CadAI-B for Breast, outcomesModule primaryOutcomes measure: Area Under the LROC Curve, secondaryOutcomes measure: Lesion detection sensitivity and specificity, eligibilityModule sex: FEMALE, minimumAge: 19 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Yonsei University Severance Hospital, city: Seoul, zip: 03722, country: Korea, Republic of, geoPoint lat: 37.566, lon: 126.9784, hasResults: False
protocolSection identificationModule nctId: NCT06352671, orgStudyIdInfo id: 023-286, briefTitle: Prospective Long-Term Outcomes of a Standardized Ross Procedure, acronym: ROSS, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-10-12, primaryCompletionDateStruct date: 2025-12-01, completionDateStruct date: 2026-01-01, studyFirstPostDateStruct date: 2024-04-08, lastUpdatePostDateStruct date: 2024-04-08, sponsorCollaboratorsModule leadSponsor name: Baylor Research Institute, class: OTHER, descriptionModule briefSummary: This standardized prospective long-term outcome analysis will help reaffirm these findings via a multicenter patient cohort and describe the best practices/techniques for stabilization of the autograft and right ventricular outflow tract reconstruction., conditionsModule conditions: Ross Procedure (Pulmonary Autograft Replacement), designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 225, type: ESTIMATED, outcomesModule primaryOutcomes measure: Survival of the patient at 1-, 5- and 10-year intervals, secondaryOutcomes measure: Rate of re-hospitalization, secondaryOutcomes measure: Rate of peri operative morbidity, secondaryOutcomes measure: Rate of re-operation, secondaryOutcomes measure: Rate of re-intervention, secondaryOutcomes measure: NYHA status, secondaryOutcomes measure: Anticoagulant usage, secondaryOutcomes measure: Bleeding events, secondaryOutcomes measure: Post operative infection, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 90 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Baylor Scott and White Heart Hospital, status: RECRUITING, city: Plano, state: Texas, zip: 75093, country: United States, contacts name: Rincy Rajan, role: CONTACT, phone: 469-814-4981, email: Rincy.Rajan@BSWHealth.org, contacts name: Sarah Hale, role: CONTACT, phone: 4698144845, email: sarah.hale@bswhealth.org, contacts name: William Brinkman, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 33.01984, lon: -96.69889, hasResults: False
protocolSection identificationModule nctId: NCT06352658, orgStudyIdInfo id: #1/2024, briefTitle: Efficacy of Mandibular Advancement Device for Mild-Moderate Apnea, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-02-01, primaryCompletionDateStruct date: 2024-01-01, completionDateStruct date: 2024-01-10, studyFirstPostDateStruct date: 2024-04-08, lastUpdatePostDateStruct date: 2024-04-08, sponsorCollaboratorsModule leadSponsor name: Nourhan M.Aly, class: OTHER, descriptionModule briefSummary: This was a prospective randomized controlled clinical trial that aimed to compare the efficacy of conventional and CAD CAM mandibular advancement device., conditionsModule conditions: Apnea, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 26, type: ACTUAL, armsInterventionsModule interventions name: Conventional mandibular advancement device, interventions name: CAD CAM mandibular advancement device, outcomesModule primaryOutcomes measure: Apnea hypopnea index, primaryOutcomes measure: Epwoth sleeplness scale (ESS), primaryOutcomes measure: Oxygen saturation, primaryOutcomes measure: Snoring index, eligibilityModule sex: ALL, minimumAge: 30 Years, maximumAge: 50 Years, stdAges: ADULT, contactsLocationsModule locations facility: Faculty of Dentistry, Alexandria University, Egypt, city: Alexandria, country: Egypt, geoPoint lat: 31.21564, lon: 29.95527, hasResults: False
protocolSection identificationModule nctId: NCT06352645, orgStudyIdInfo id: STUDY00004879, briefTitle: Evaluation of Safety and Efficacy of Bixdo Ultra Compact Water Flosser, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2025-05-01, completionDateStruct date: 2026-05-01, studyFirstPostDateStruct date: 2024-04-08, lastUpdatePostDateStruct date: 2024-04-09, sponsorCollaboratorsModule leadSponsor name: Tufts University, class: OTHER, collaborators name: Guangdong Bixdo Health Technology Co., Ltd., descriptionModule briefSummary: The objective of the present randomized controlled trial is to evaluate the safety and efficacy of the use of Bixdo A30 Pro Ultra Compact Water Flosser (also referred to as the "Bixdo A30 Portable Water Flosser Travel Set") in addition to a manual toothbrush on clinical parameters of inflammation and bacterial plaque removal., conditionsModule conditions: Plaque Induced Gingivitis, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: randomized controlled clinical trial, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 165, type: ESTIMATED, armsInterventionsModule interventions name: Bixdo Ultra Compact Water Flosser, interventions name: Manual toothbrush, outcomesModule primaryOutcomes measure: Inflammation Reduction, primaryOutcomes measure: Bacterial plaque removal, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Tufts University School of Dental Medicine, city: Boston, state: Massachusetts, zip: 02111, country: United States, geoPoint lat: 42.35843, lon: -71.05977, hasResults: False
protocolSection identificationModule nctId: NCT06352632, orgStudyIdInfo id: ACT-GLOBAL_Master, briefTitle: A Multi-faCtorial, mulTi-arm, Multi-staGe, Randomised, gLOBal Adaptive pLatform Trial for Stroke, acronym: ACT-GLOBAL, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2024-04, completionDateStruct date: 2034-04, studyFirstPostDateStruct date: 2024-04-08, lastUpdatePostDateStruct date: 2024-04-23, sponsorCollaboratorsModule leadSponsor name: The George Institute, class: OTHER, collaborators name: University of Calgary, collaborators name: Berry Consultants, descriptionModule briefSummary: Stroke is causing 6.6 million deaths and is a major cause of disability worldwide in 2019. There remains an urgent need for interventions that improve outcomes which can be implemented with wide applicability for stroke. ACT-GLOBAL is a multi-factorial, multi-arm, multi-stage, randomised, global adaptive platform trial for stroke, aiming to identify the treatment/s associated with the highest chance of improving outcome in stroke patients. In ACT-GLOBAL multiple questions will be evaluated simultaneously and sequentially as data accrues and can evaluate interactions between different treatment options., conditionsModule conditions: Stroke, designModule studyType: INTERVENTIONAL, phases: PHASE3, designInfo allocation: RANDOMIZED, interventionModel: FACTORIAL, interventionModelDescription: Adaptive Platform Trial evaluating multiple interventions in multiple domains, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 20000, type: ESTIMATED, armsInterventionsModule interventions name: Standard-dose intravenous tenecteplase, interventions name: Low-dose intravenous tenecteplase, interventions name: No intravenous tenecteplase, interventions name: Conservative Blood Pressure Control, interventions name: Moderate Blood Pressure Control, interventions name: Intensive Blood Pressure Control, interventions name: Placebo, interventions name: NoNO-42, outcomesModule primaryOutcomes measure: modified Rankin scale (mRS) scores, secondaryOutcomes measure: Excellent functional neurological outcome, secondaryOutcomes measure: Independent functional neurological outcome, secondaryOutcomes measure: Health Related Quality of Life, otherOutcomes measure: Mortality, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06352619, orgStudyIdInfo id: ACT-GLOBAL_AIS_03, briefTitle: Third Enhanced Control of Hypertension and Thrombectomy Stroke Domain Within ACT-GLOBAL Adaptive Platform Trial, acronym: ENCHANTED3/MT, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2026-04, completionDateStruct date: 2026-04, studyFirstPostDateStruct date: 2024-04-08, lastUpdatePostDateStruct date: 2024-04-23, sponsorCollaboratorsModule leadSponsor name: The George Institute, class: OTHER, collaborators name: University of Calgary, collaborators name: Changhai Hospital, descriptionModule briefSummary: Several clinical trials have produced variable conclusions regarding the effects of intensive blood pressure (BP) lowering in post-EVT acute ischaemic stroke (AIS) patients. Although two trials indicate harm from very intensive target-based treatment (SBP \<130 mmHg), the others neutral effects in the SBP range 140-160 mmHg. The ENCHANTED3/MT domain of the ACT-GLOBAL platform trial aims to test different approaches to the treatment of elevated SBP in post-EVT AIS patients to find an optimal BP management strategy. ENCHANTED3/MT will randomize (1:1:1) up to 2,000 patients with SBP ≥150 mmHg post-EVT to conservative (no or minimal SBP reduction by 5-10mmHg or a target of 175-180mmHg if very-high baseline SBP \[≥180mmHg\]), moderate (SBP reduction by 10-20mmHg or a target of 160 ± 5, whichever is higher; no control if low-high baseline SBP \[150-160mmHg\]), or intensive (SBP reduction by 30-50mmHg or a target of 140±5 mmHg, whichever is higher) BP management., conditionsModule conditions: Ischemic Stroke, Acute, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 2000, type: ESTIMATED, armsInterventionsModule interventions name: Conservative SBP Control, interventions name: Moderate SBP Control, interventions name: Intensive SBP Control, outcomesModule primaryOutcomes measure: modified Rankin scale, secondaryOutcomes measure: Excellent functional neurological outcome, secondaryOutcomes measure: Independent functional neurological outcome, secondaryOutcomes measure: Health Related Quality of Life, secondaryOutcomes measure: Mortality, secondaryOutcomes measure: Ordinal shift of 7 levels of modified Rankin scale, secondaryOutcomes measure: National Institute of Health Stroke Scale (NIHSS) score, secondaryOutcomes measure: Any intracranial haemorrhage (ICH), secondaryOutcomes measure: Symptomatic intracerebral haemorrhage (sICH), secondaryOutcomes measure: Serious Adverse Event (SAE), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06352606, orgStudyIdInfo id: 36264PR558/2/24, briefTitle: Spinal and General Anesthesia in Neonates Undergoing Herniorrhaphy, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-06, primaryCompletionDateStruct date: 2024-09-01, completionDateStruct date: 2024-09-01, studyFirstPostDateStruct date: 2024-04-08, lastUpdatePostDateStruct date: 2024-04-09, sponsorCollaboratorsModule leadSponsor name: Tanta University, class: OTHER, descriptionModule briefSummary: The aim of this study is to compare spinal and general anesthesia in neonates undergoing herniorrhaphy., conditionsModule conditions: Spinal Anesthesia, conditions: General Anesthesia, conditions: Neonates, conditions: Inguinal Herniorrhaphy, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: DIAGNOSTIC, maskingInfo masking: NONE, enrollmentInfo count: 74, type: ESTIMATED, armsInterventionsModule interventions name: Spinal anesthesia, interventions name: General anesthesia, outcomesModule primaryOutcomes measure: Heart rate, secondaryOutcomes measure: Heart rate, secondaryOutcomes measure: Mean arterial blood pressure, secondaryOutcomes measure: Incidence of bradycardia, secondaryOutcomes measure: Incidence of hypotension, secondaryOutcomes measure: Incidence of postoperative apnea, secondaryOutcomes measure: The duration of surgery, secondaryOutcomes measure: Need for postoperative O2 supplementation, secondaryOutcomes measure: Hospital stays, eligibilityModule sex: ALL, minimumAge: 1 Day, maximumAge: 1 Month, stdAges: CHILD, contactsLocationsModule locations facility: Tanta University Hospitals, status: RECRUITING, city: Tanta, state: ElGharbia, zip: 31527, country: Egypt, contacts name: Mohammed S Elsharkawy, MD, role: CONTACT, phone: 00201148207870, email: mselsharkawy@med.tanta.edu.eg, contacts name: Ahmed E Abo ElKheir, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 30.78847, lon: 31.00192, hasResults: False
protocolSection identificationModule nctId: NCT06352593, orgStudyIdInfo id: 36264PR557/2/24, briefTitle: Intraoperative Dexmedetomidine Infusion in Endovascular Intervention for Aneurysmal Subarachnoid Hemorrhage, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-06, primaryCompletionDateStruct date: 2024-09-01, completionDateStruct date: 2024-09-01, studyFirstPostDateStruct date: 2024-04-08, lastUpdatePostDateStruct date: 2024-04-09, sponsorCollaboratorsModule leadSponsor name: Tanta University, class: OTHER, descriptionModule briefSummary: The aim of this study is to evaluate the role of intraoperative dexmedetomidine infusion in endovascular intervention for aneurysmal subarachnoid hemorrhage., conditionsModule conditions: Dexmedetomidine, conditions: Infusion, conditions: Endovascular, conditions: Aneurysmal Subarachnoid Hemorrhage, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: TRIPLE, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 90, type: ESTIMATED, armsInterventionsModule interventions name: Intraoperative Dexmedetomidine, interventions name: Placebo, outcomesModule primaryOutcomes measure: Incidence of vasospasm, secondaryOutcomes measure: Incidence of morbidity and mortality (M/M), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Tanta University Hospitals, status: RECRUITING, city: Tanta, state: ElGharbia, zip: 31527, country: Egypt, contacts name: Mohammed S Elsharkawy, MD, role: CONTACT, phone: 00201148207870, email: mselsharkawy@med.tanta.edu.eg, contacts name: Ahmed E Abo ElKheir, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 30.78847, lon: 31.00192, hasResults: False
protocolSection identificationModule nctId: NCT06352580, orgStudyIdInfo id: COVID-19 Pediatric, briefTitle: Covid-19 Pandemic and Pediatric Dentistry, statusModule overallStatus: COMPLETED, startDateStruct date: 2022-03-01, primaryCompletionDateStruct date: 2022-06-30, completionDateStruct date: 2022-06-30, studyFirstPostDateStruct date: 2024-04-08, lastUpdatePostDateStruct date: 2024-04-08, sponsorCollaboratorsModule leadSponsor name: Abant Izzet Baysal University, class: OTHER, descriptionModule briefSummary: Coronavirus (SARS-CoV-2), which emerged in Wuhan, China in 2019 and causes severe respiratory infection, poses a potential risk for dentists and patients during dental treatments. It is a common situation during the pandemic period for parents of children needing dental treatment to want to postpone their children's treatment due to Covid-19. This study aimed to evaluate parents' concerns about their children's dentist appointments and ongoing dental treatments in the presence of the quarantine imposed due to Covid-19 and the Covid-19 vaccines that have started to be administered worldwide. In the study, an informative survey consisting of 26 questions was applied to determine how parents feel about the COVID-19 pandemic, how concerned they are about their children's oral health and dental treatment plan, and the changes caused by COVID-19 vaccination practices. The questions were created by 3 different experienced dentists and analysed by 2 different experienced dentists. Questions 7 and 26 were repeated at the beginning and end of the survey to give the same question and answer meaning. Thus, the reliability of the survey was tested., conditionsModule conditions: COVID-19 Pandemic, designModule studyType: OBSERVATIONAL, designInfo observationalModel: FAMILY_BASED, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 438, type: ACTUAL, armsInterventionsModule interventions name: Survey, outcomesModule primaryOutcomes measure: Approach to dental treatments, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Deniz Sıla Özdemir Çelik, city: Merkez, state: Bolu, zip: 14030, country: Turkey, hasResults: False
protocolSection identificationModule nctId: NCT06352567, orgStudyIdInfo id: BakircayU1394/1414, briefTitle: Symptoms Associated With Chemotherapy-Induced Peripheral Neuropathy, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-01-18, primaryCompletionDateStruct date: 2024-06-22, completionDateStruct date: 2024-08, studyFirstPostDateStruct date: 2024-04-08, lastUpdatePostDateStruct date: 2024-04-09, sponsorCollaboratorsModule leadSponsor name: Izmir Bakircay University, class: OTHER, descriptionModule briefSummary: Breast cancer remains the most frequent type of cancer globally. Nevertheless, the increased rate of disease-free survival of breast cancer brought the specific need of managing of short and long-term side effects of multimodal treatment. Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most debilitating conditions which is characterized by a wide variety of experienceable symptoms by patients that need to be addressed in detail. Therefore, in this cross-sectional study, it was aimed to assess the potential symptoms associated with CIPN of patients with breast cancer who underwent systemic chemotherapy. In addition, it was aimed to assess the potential associations between experienced symptoms of CIPN and sociodemographic (age, body mass index etc.) and clinical features (mean exposed dose, type of surgery (if any) etc.)., conditionsModule conditions: Chemotherapy-induced Peripheral Neuropathy, conditions: Breast Cancer, conditions: Breast Cancer Female, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_ONLY, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 112, type: ESTIMATED, armsInterventionsModule interventions name: European Organization for Research and Treatment of Cancer-Chemotherapy Induced Peripheral Neuropathy (EORTC-CIPN20) questionnaire, outcomesModule primaryOutcomes measure: Assessment of perceived Chemotherapy Induced Peripheral Neuropathy symptoms, eligibilityModule sex: FEMALE, minimumAge: 18 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Bakircay University Çiğli State and Training Hospital, Department of Medical Oncology, status: RECRUITING, city: İzmir, state: Çiğli, zip: 35620, country: Turkey, contacts name: Murat Akyol, MD, role: CONTACT, phone: +902324930000, email: dr-muratakyol@hotmail.com, contacts name: Alper Tuğral, PT, MSc, role: CONTACT, phone: +905074421420, email: alper.tugral@bakircay.edu.tr, geoPoint lat: 38.41273, lon: 27.13838, hasResults: False